Taken together, MLN4924 conferred resistance of cancer cells to T cells-mediated cytotoxicity by inducing PD-L1 and the immune checkpoint, which is abrogated by blocking MEK pathway-regulated PD-L1 transcription or anti-PD-L1 antibody shown in both in vitro and one CT26 in vivo model. This evidence concerns the gene CD274 and cancer.